PolyPid (PYPD) 20-F 5 Mar 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information Line Items
Entity Registrant Name	PolyPid Ltd.
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	18,494,739
Amendment Flag	false
Entity Central Index Key	0001611842
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity File Number	001-38428
Entity Incorporation, State or Country Code	L2
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 4,319	$ 3,924
Restricted cash	390	375
Short-term deposits	40,157	22,685
Prepaid expenses and other receivables	2,334	417
Total current assets	47,200	27,401
Long-term assets:
Property and equipment, net	5,890	6,121
Long-term deposits	22,120
Other long-term assets	637	230
Total long-term assets	28,647	6,351
Total assets	75,847	33,752
CURRENT LIABILITIES:
Trade payables	974	1,581
Other payables and accrued expenses	1,903	998
Total current liabilities	2,877	2,579
Long-term liabilities:
Other liabilities	193	251
Warrants to convertible preferred shares		12,241
Total long-term liabilities	193	12,492
Commitments and Contingencies
Convertible preferred shares: Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares with no par value - Authorized: 0 and 17,916,412 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 0 and 12,520,977 shares at December 31, 2020 and 2019, respectively.		106,313
Shareholders’ equity (deficit):
Share capital - Ordinary shares with no par value - Authorized: 47,800,000 and 22,520,977 shares at December 31, 2020 and 2019, respectively; Issued and outstanding: 18,494,739 and 562,748 shares at December 31, 2020 and 2019, respectively.
Additional paid-in capital	205,063	5,671
Accumulated deficit	(132,286)	(93,303)
Total shareholders’ equity (deficit)	72,777	(87,632)
Total liabilities, convertible preferred shares and shareholders’ equity (deficit)	$ 75,847	$ 33,752

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, par value (in Dollars per share)
Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares authorized	0	17,916,412
Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares, issued	0	12,520,977
Preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 stock, shares outstanding	0	12,520,977
Common stock, par value (in Dollars per share)
Common stock, shares authorized	47,800,000	22,520,977
Common stock, shares, issued	18,494,739	562,748
Common stock, shares outstanding	18,494,739	562,748

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development, net	$ 16,954	$ 14,083	$ 12,550
Marketing and business development expenses	1,614	887	549
General and administrative	7,704	3,590	5,265
Operating loss	26,272	18,560	18,364
Financial (income) expense, net	10,597	(11,655)	(24,281)
Net (profit) loss	36,869	6,905	(5,917)
Deemed dividend	2,114
Net loss attributable to Ordinary shares	$ 38,983	$ 6,905	$ (5,917)
Basic net (profit) loss per Ordinary share (in Dollars per share)	$ 4.48	$ 23.69	$ (0.16)
Diluted net loss per Ordinary share (in Dollars per share)	$ 4.48	$ 23.69	$ 0.86
Weighted average number of Ordinary shares used in computing basic net (profit) loss per share (in Shares)	9,582,405	562,451	561,113
Weighted average number of Ordinary shares used in computing diluted net loss per share (in Shares)	9,582,405	562,451	613,358

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders’ Equity (Deficit) - USD ($) $ in Thousands		Convertible Preferred Shares	Number of ordinary shares	Additional Paid-In Capital	Accumulated deficit	Total
Balance at Dec. 31, 2017		$ 59,983		$ 3,669	$ (92,315)	$ (88,646)
Balance (in Shares) at Dec. 31, 2017		8,736,425	558,447
Exercise of Options				24		24
Exercise of Options (in Shares)			2,778
Share-based compensation				995		995
Issuance of series E-1 Preferred shares, net	[1]	$ 9,364
Issuance of series E-1 Preferred shares, net (in Shares)	[1]	718,008
Net profit(loss)					5,917	5,917
Balance at Dec. 31, 2018		$ 69,347		4,688	(86,398)	(81,710)
Balance (in Shares) at Dec. 31, 2018		9,454,433	561,225
Exercise of Options				7		7
Exercise of Options (in Shares)			1,523
Share-based compensation				976		976
Issuance of series E-1 Preferred shares, net	[2]	$ 36,966
Issuance of series E-1 Preferred shares, net (in Shares)	[2]	3,066,544
Net profit(loss)					(6,905)	(6,905)
Balance at Dec. 31, 2019		$ 106,313		5,671	(93,303)	(87,632)
Balance (in Shares) at Dec. 31, 2019		12,520,977	562,748
Exercise of Options				3		3
Exercise of Options (in Shares)			395
Share-based compensation				4,577		4,577
Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e)				62,757		62,757
Issuance of Ordinary shares in connection with IPO, net of issuance costs of $6,243 (see Note 1e) (in Shares)			4,312,500
Conversion of Convertible Preferred shares to Ordinary shares		$ (106,313)		106,313		106,313
Conversion of Convertible Preferred shares to Ordinary shares (in Shares)		(12,520,977)	12,520,977
Deemed dividend related to Series E-1 Preferred shares (see Note 9e)				2,114	(2,114)
Deemed dividend related to Series E-1 Preferred shares (see Note 9e) (in Shares)			158,967
Reclassification of Warrants into equity				23,614		23,614
Exercise of Warrants				13		13
Exercise of Warrants (in Shares)			939,152
Issuance of Warrants				1		1
Net profit(loss)					(36,869)	(36,869)
Balance at Dec. 31, 2020				$ 205,063	$ (132,286)	$ 72,777
Balance (in Shares) at Dec. 31, 2020			18,494,739
[1]	Net of issuance costs of $187 in cash.
[2]	Net of issuance costs of $3,822 in cash and warrants.

Consolidated Statements of Co_2

Consolidated Statements of Convertible Preferred Shares and Changes in Shareholders’ Equity (Deficit) (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 3,822	$ 187

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net profit (loss)	$ (36,869)	$ (6,905)	$ 5,917
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,012	947	411
Re-evaluation of warrants	11,373	(11,365)	(24,473)
Share-based compensation	4,577	976	995
Changes in assets and liabilities:
Decrease (increase) in receivables and prepaid expenses	(1,917)	69	306
Decrease in deferred equity offering costs			1,088
Decrease in advance on account of collaboration agreement			(600)
Decrease (increase) in other long-term assets	(12)	11	5
Increase (decrease) in trade payables	(607)	449	(887)
Increase (decrease) in other payables and accrued expenses and other liabilities	847	(1,540)	560
Net cash used in operating activities	(21,596)	(17,358)	(16,678)
Cash flows from investing activities:
Short-term deposits, net	(17,472)	(22,685)	14,031
Long-term deposits, net	(22,120)
Pre-payment for equipment	(395)
Purchase of property and equipment	(781)	(879)	(3,074)
Net cash provided by (used in) investing activities	(40,768)	(23,564)	10,957
Cash flows from financing activities:
Proceeds from issuance of convertible Preferred shares, net		37,646	9,364
Proceeds from Issuance of Ordinary shares in connection with IPO, net	62,757
Exercise of warrants	13
Issuance of warrants	1
Proceeds from exercise of options	3	7	24
Net cash provided by financing activities	62,774	37,653	9,388
Increase (decrease) in cash, cash equivalents and restricted cash	410	(3,269)	3,667
Cash, cash equivalents and restricted cash at the beginning of the year	4,498	7,767	4,100
Cash, cash equivalents and restricted cash at the end of the year	$ 4,908	4,498	7,767
Non-cash activity:
Purchase of property and equipment included in trade payable			$ 600
Issuance of E-1 warrants		$ 680

General

General	12 Months Ended
	Dec. 31, 2020
General [Abstract]
GENERAL	NOTE 1:- GENERAL a. PolyPid Ltd. (the “Company”) was incorporated under the laws of Israel and commenced operations on February 28, 2008. The Company is a clinical-stage pharmaceutical company focused on developing and commercializing novel, locally administered therapies using its PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of its lead product candidate, D-PLEX, which incorporates an antibiotic, for the prevention of surgical site infection in bone and soft tissue. The Company wholly-owns subsidiaries in the Unites States of America and Romania. Through December 31, 2020, the Company has been primarily engaged in research and development. b. The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete phase III clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company’s product candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. As of December 31, 2020, the Company had cash, cash equivalents, short-term deposits and long-term deposits of $66,596. During the year ended December 31, 2020, the Company incurred a net loss of $36,869 and had negative cash flows from operating activities of $21,596. In addition, the Company had an accumulated deficit of $132,286 at December 31, 2020. The Company’s future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company’s product candidates. There can be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above. c On March 11, 2020, the World Health Organization declared the outbreak of a respiratory disease caused by a new coronavirus as a “pandemic” which is now known as COVID-19. The outbreak has impacted thousands of individuals worldwide. In response, many countries have implemented measures to combat the outbreak which have impacted global business operations. The Company’s business is likely to be adversely affected by the effects of the recent and evolving COVID-19 pandemic, which has resulted in travel and other restrictions in order to reduce the spread of the disease, including in Israel, the United States and the European Union where the Company is conducting or planning clinical trials. No impairments were recorded as of the balance sheet date as no triggering events or changes in circumstances had occurred; however, due to significant uncertainty surrounding the situation, management’s judgment regarding this could change in the future. d. On June 21, 2020, the Company’s Board of Directors resolved to consolidate the Company’s share capital by applying a reverse share split at a ratio of 1.046:1 (the “Reverse Split Ratio”) and to cancel the shares’ par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the “Split”). The Split was applied in the same proportion and manner to all of the Company’s authorized, issued and outstanding securities, including preferred shares, options and warrants. See Note 10. e. On June 30, 2020, the Company closed its initial public offering (“IPO”) whereby 4,312,500 Ordinary shares were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $62,757, net of underwriting discounts and other offering costs.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”) a. Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. b. Consolidated financial statements in U.S. dollars: The accompanying consolidated financial statements have been prepared in U.S. dollars. A substantial portion of the Company’s expenses are incurred in New Israeli Shekels (“NIS”). However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters”. All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate. c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation. d. Reclassifications: Certain prior years amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated net loss. e. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at the date acquired. f. Restricted cash: Restricted cash is primarily invested in certificates of deposit and is used as security for the Company’s lease commitments and hedging activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows: December 31, 2020 2019 Cash and cash equivalents, as reported on the balance sheets $ 4,319 $ 3,924 Restricted cash, as reported on the balance sheets 390 375 Restricted cash in other long-term assets, as reported on the balance sheets 199 199 Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows $ 4,908 $ 4,498 g. Short-term deposits: A Short-term bank deposit is a deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value due to their short maturities. h. Long-term deposits: A Long-term bank deposit is a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per annum, as of December 31, 2020. Long-term deposits are presented at cost. i. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and laboratory equipment 15 - 33 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life Down payments for property and equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated. j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. As of December 31, 2020, no impairment losses have been identified. k. Research and development expenses: Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company’s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred. l. Basic and diluted net loss (profit) per share: The Company computes net loss (profit) per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require the holders of such shares to participate in the Company’s losses. As such, during the periods when the Company is in a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company’s losses. The Company’s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive. m. Accounting for share-based payments: Share-based compensation expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company’s Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. Forfeitures are accounted for as they occur instead of estimating the number of awards expected to be forfeited. n. Grants and participations: Royalty-bearing grants from the Israeli Innovation Authority (“IIA”) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission’s Seventh Framework Programme for Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognizes participations in research and development, as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research and development expenses incurred during the period is recognized as other income within operating income. o. Convertible preferred shares and convertible preferred shares warrant liability: The terms of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares allowed the holders to redeem shares, under certain circumstances, outside of the Company’s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as a component of shareholders’ deficit before the IPO. The carrying value of the convertible preferred shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the convertible preferred shares will be redeemed. Warrants to purchase the Company’s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation. p. Fair value of financial instruments: The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: ● Level 1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities. ● Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. ● Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value . The financial instruments carried at fair value on the Company’s consolidated balance sheets as of December 31, 2019 are warrants to convertible preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7. The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments: The carrying amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. q. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value, if needed. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was recorded as a result of ASC 740. The Company’s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income. r. Concentration of credit risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be in excess of insured limits and are not insured. in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk. The Company utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions. s. Severance pay: All the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheets. Severance pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively. t. Derivative financial instruments: The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and hedging”, as amended and related interpretations (“ASC 815”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions) or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions). The ineffective portion of a derivative’s change in fair value is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as “financial income, net”. The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was $62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December 31, 2019 and 2018 amounted to $10 and $0, respectively. u. Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate. v. Recently adopted Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election . In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting,” which simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. The Company adopted the guidance as of January 1, 2020. The adoption of the standard didn’t have a material impact on the Company’s consolidated statements of operations. w. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases,” which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU 2016-02 will have on its consolidated financial statements. In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements, expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its Consolidated Statements of Operations or Cash Flows. In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2018-15 will have on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by removing a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12 will have on its consolidated financial statements and related disclosures.

Prepaid Expenses and Other Rece

Prepaid Expenses and Other Receivables	12 Months Ended
	Dec. 31, 2020
Prepaid Expenses And Other Receivables [Abstract]
PREPAID EXPENSES AND OTHER RECEIVABLES	NOTE 3:- PREPAID EXPENSES AND OTHER RECEIVABLES December 31, 2020 2019 Government authorities $ 283 $ 177 Prepaid expenses 1,888 180 Lease deposits 24 18 Others 139 42 $ 2,334 $ 417

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 4:- PROPERTY AND EQUIPMENT, NET December 31, 2020 2019 Cost: Computers and software $ 449 $ 389 Laboratory equipment 3,947 3,356 Furniture and office equipment 152 147 Leasehold improvements 4,478 4,353 9,026 8,245 Accumulated depreciation (3,136 ) (2,124 ) Depreciated cost $ 5,890 $ 6,121 Depreciation expenses amounted to $1,012, $947 and $411 for the years ended December 31, 2020, 2019 and 2018, respectively.

Other Payables and Accrued Expe

Other Payables and Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
OTHER PAYABLES AND ACCRUED EXPENSES	NOTE 5:- OTHER PAYABLES AND ACCRUED EXPENSES December 31, 2020 2019 Employees and payroll accruals $ 971 $ 673 Accrued expenses 681 319 IIA deferred grant 241 - Other expenses 10 6 $ 1,903 $ 998

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6:- COMMITMENTS AND CONTINGENT LIABILITIES a. The Company’s facilities are leased under operating lease agreements for periods ending no later than 2027. The Company also leases motor vehicles under various operating leases, the latest of which expires in 2023. Future minimum lease payments under operating leases as of December 31, 2020 are as follows: As of December 31, 2020 2021 1,236 2022 1,181 2023 995 2024 283 2025 283 Thereafter 425 $ 4,403 As of December 31, 2020, the Company made advance payments on account of car leases in the amount of $75. Rental and lease expenses for the years ended December 31, 2020, 2019 and 2018 were $1,035, $ 1,027 and $1,073, respectively. b. In connection with its research and development programs, through December 31, 2020, the Company received participation payments from the IIA in the aggregate amount of $5,139. In return for IIA’s participation, the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2020, no royalties have been paid or accrued. c. On December 22, 2016, the Company received a written demand for a finder’s fee in an amount of $250, in connection with the second financing round that occurred in 2016. In September 2017, a suit was filed against the Company in the Tel-Aviv Magistrates Court in an amount of $250. On April 30, 2020, the Company received the court ruling, which ruled in favor of the Company, discharging the entire claim, and accordingly reversed the related provision. d. On January 9, 2020, the Company entered into an agreement for an automatic filling machine for the Company’s manufacturing plant in a total amount of EUR 1,326. The Company paid a pre-payment of EUR 372 and will pay the remaining of the payments during 2021 according to the milestones of the agreement.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 7:- FAIR VALUE MEASUREMENTS Financial instruments measured at fair value on a recurring basis include warrants to convertible preferred shares (see Note 9). The warrants are classified as a liability in accordance with ASC 480-10-25. These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation (the share price) were determined based on management’s assumptions. To calculate the fair value of the warrants, the Company first calculated the underlying preferred share value by using the income approach and the market approach. Then the equity value was allocated by using the hybrid model method utilizing two scenarios of option pricing model and IPO. Once the preferred shares value was derived from the two scenarios, the Black-Scholes model was utilized to calculate the warrants’ value in each one of the scenarios. 50% probability for each one of the scenarios was applied to derive the weighted average fair value of the warrants. As of December 31, 2019: According to the liquidation scenario the underlying share price was between $13.25 - $13.40 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value of the series E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 69.11%, risk free interest rates of 1.82%, dividend yield of 0%, and expected term of 2.25 years. Under the IPO scenario the underlying share price was $12.18 for the Convertible Preferred E-1 shares. The following assumptions were used to estimate the value of the series E-1 Preferred share warrants as of December 31, 2019 (exercise price of $15.95): expected volatility of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series E-1 Preferred share warrants as of December 31, 2019 was $563. According to the liquidation scenario, the underlying share price was $10.29 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series D-2 Preferred share warrants as of December 31, 2019 (exercise price of $9.24): expected volatility of 69.11%, risk free interest rates of 1.82%, dividend yield of 0% and expected term of 2.25 years. Under the IPO scenario, the underlying share price was $12.18 for the Convertible Preferred D-2 shares. The following assumptions were used to estimate the value of the series D-2 Preferred share warrants as of December 31, 2019 (exercise price of $9.24): expected volatility of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series D-2 Preferred share warrants as of December 31, 2019 was $11,275. According to the liquidation scenario, the underlying share price was $4.35 for the Convertible Preferred A shares. The following assumptions were used to estimate the value of the series A Preferred share warrants as of December 31, 2019 (exercise price of NIS 0.84 ($0.24)): expected volatility of 69.11%, risk free interest rates of 1.82%, dividend yield of 0% and expected term of 2.25 years. Under the IPO scenario, the underlying share price was $12.18 for the Convertible Preferred A shares. The following assumptions were used to estimate the value of the series A Preferred share warrants as of December 31, 2019 (exercise price of NIS 0.84 ($0.24)): expected volatility of 64.03%, risk free interest rates of 1.87%, dividend yield of 0%, and expected term of 0.42 years. Accordingly, the fair value of the series A Preferred share warrants as of December 31, 2019 was $403. As of June 30, 2020: According to the IPO scenario, the underlying share price was $16 for the series E-1 Preferred shares. The following assumptions were used to estimate the value of the series E-1 Preferred share warrants as of June 30, 2020: exercise price of $15.95, expected volatility of 78.07%, risk free interest rates of 0.76%, dividend yield of 0%, and expected term of 4.17 years. Accordingly, the fair value of the series E-1 Preferred share warrants as of June 30, 2020 was $1,868. According to the IPO scenario, the underlying share price was $16 for the series D-2 Preferred shares. The following assumptions were used to estimate the value of the series D-2 Preferred share warrants as of June 30, 2020: exercise price of $9.24, expected volatility of 82.48%, risk free interest rates of 0.46%, dividend yield of 0%, and expected term of 0.6 years. Accordingly, the fair value of the series D-2 Preferred share warrants as of June 30, 2020 was $20,930. As of June 30, 2020, as part of the IPO 1,123,570 Warrants have been exercised on cashless basis into 475,049 Ordinary shares. According to the IPO scenario, the underlying share price was $16 for the series A Preferred shares. The following assumptions were used to estimate the value of the series A Preferred share warrants as of June 30, 2020: exercise price of 0.84 NIS ($0.23) and dividend yield of 0%. Accordingly, the fair value of the series A Preferred share warrants as of June 30, 2020 was $816. As of June 30, 2020, as part of the IPO, 53,775 Warrants have been exercised into 53,775 Ordinary shares. On June 30, 2020, as a result of the IPO, the warrant liability to Convertible Preferred shares has been classified to Warrants to Ordinary shares in equity. The change in the fair value of the Preferred share warrant liability is summarized below: December 31, 2020 2019 Beginning of year $ 12,241 $ 22,926 Issuance of warrants - 680 Change in fair value 11,373 (11,365 ) Reclassification of Warrants into equity (23,614 ) - End of period $ - $ 12,241

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8:- INCOME TAXES a. Corporate tax rates: The corporate tax rate in Israel in 2020, 2019 and 2018 was 23%. b. Net operating losses carryforward: The Company has accumulated losses for tax purposes as of December 31, 2020 in the amount of approximately $96,385 which may be carried forward and offset against taxable income in the future for an indefinite period. c. Deferred taxes: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets are comprised of operating loss carryforwards and other temporary differences. Significant components of the Company’s deferred tax assets are as follows: December 31, 2020 2019 Reserves and allowances $ 190 $ 173 Temporary differences 3,644 2,204 Issuance costs 957 - Loss carryforward 22,168 15,406 Deferred tax assets before valuation allowance 26,959 17,783 Less - valuation allowance (26,959 ) (17,783 ) Net deferred tax assets $ - $ - Management currently believes that since the Company has a history of losses, and there is uncertainty with respect to future taxable income of the Company, it is more likely than not that the deferred tax assets will not be utilized in the foreseeable future. Thus, a full valuation allowance was provided to reduce deferred tax assets to their realizable value. In 2019 and 2018, the main reconciling item of the Company’s statutory tax rate of 23% and the effective tax rate of 0% is tax loss carryforwards, for which a full valuation allowance was provided. d. Tax assessment: The Company has net operating losses from prior tax periods which may be subjected to examination in future periods. As of December 31, 2020, the Company’s tax years until December 31, 2015 are subject to the statute of limitation in Israel.

Convertible Preferred Shares an

Convertible Preferred Shares and Warrants	12 Months Ended
	Dec. 31, 2020
Convertible Preferred Shares And Warrants [Abstract]
CONVERTIBLE PREFERRED SHARES AND WARRANTS	NOTE 9:- CONVERTIBLE PREFERRED SHARES AND WARRANTS a. The Composition of the Company’s Convertible Preferred shares is as follows: December 31, 2020 December 31, 2019 Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Series A Convertible Preferred shares with no par value - - 537,750 483,975 Series A-1 Convertible Preferred shares with no par value - - 896,250 798,950 Series B Convertible Preferred shares with no par value - - 597,500 566,386 Series B-1 Convertible Preferred shares with no par value - - 1,867,562 1,751,309 Series C-1 Convertible Preferred shares with no par value - - 717,000 645,923 Series C-2 Convertible Preferred shares with no par value - - 454,100 410,197 Series D-1 Convertible Preferred shares of NIS 0 par value - - 2,509,500 2,376,512 Series D-2 Convertible Preferred shares with no par value - - 2,868,000 - Series D-3 Convertible Preferred shares with no par value - - 597,500 576,944 Series E Convertible Preferred shares with no par value - - 1,135,250 851,795 Series E-1 Convertible Preferred shares with no par value - - 5,736,000 4,058,986 Total - - 17,916,412 12,520,977 The Company issued Series A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 Preferred shares between February 2008 and September 2019. The Company classifies the convertible preferred shares outside of shareholders’ deficit as required by ASC 480-10-S99-3A and ASR 268, since these preferred shares are entitled to liquidation preferences which may trigger a distribution of cash or assets that is not solely within the Company’s control. Upon completion of the IPO, all convertible preferred shares outstanding, totaling 12,520,977 shares, were automatically converted into Ordinary shares and their carrying value of $106,300 was reclassified into shareholders’ equity. b. Preferred shares rights: Up to completion of the IPO on June 30, 2020, series A, A-1, B, B-1, C-1,C-2, D-1,D-3, E and E-1 convertible preferred shares conferred upon their holders all the rights conferred by Ordinary shares, in addition to certain rights stipulated in the Company’s previous Articles of Association (the “Previous Articles”), inter alia, the following: Dividend rights - The preference order was such that Series E-1, E, D, C-2, C-1, B-1, B, A-1 and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above order, any distribution of any asset, capital, earnings or surplus funds of the Company. After the Preference Dividend has been paid in full, the preferred shareholders’ were entitled to participate pro-rata and pari-passu, on an as converted basis with the Ordinary shareholders’ in the receipt of any additional dividend distributed. Liquidation rights - Holders of Series E-1, E preferred shares and D preferred shares were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid. The liquidation order was such that Series E-1, E, D, C-2 and C-1, B-1, B A-1, and A shareholders were entitled, in their respective order, to receive, prior and in preference to the above order any distribution of any asset, capital, earnings or surplus funds of the Company. All remaining assets shall be distributed among all the shareholders pro rata in proportion to the number of Ordinary shares held by them on an as converted basis. The original issue price of the Series A, A-1, B, B-1 and C-1 Convertible Preferred shares was $1.51, $1.76, $3.60, $5.06, and $6.95 per share, respectively, Series C-2, D-1 and D-3 was $9.23 per share and Series E and E-1 was $13.30 per share. Voting rights Conversion Each share of Series A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 was convertible into Ordinary shares on a 1-for-1 ratio. The conversion price per preferred share was to be adjusted in the event of recapitalizations, splits, Ordinary share dividends and standard anti-dilution events. c. Financing rounds: During August 2018 through February 2019, the Company entered into a Securities Purchase Agreement (the “2018 SPA”) with new and existing investors for an aggregate amount of up to $35,000. The Company received $15,577 and issued to the investors 1,187,887 series E-1 Preferred shares (net of $187 issuance costs in cash in 2018) at a price per share of $13.30. As part of the 2018 SPA, the Company converted 274,434 series E Preferred shares into series E-1 Preferred shares to holders of series E Preferred shares who participated in the 2018 SPA pursuant to the conversion rights of the 2018 SPA. During June 2019, the Company prepared a Private Placement Memorandum (the “2019 PPM”) which includes the 2018 SPA and allowed the Company to raise up to $50,000 from new and existing shareholders. From June to August 2019, the Company received $30,717 and issued to the investors 2,596,665 series E-1 Preferred shares, net of $3,142 issuance costs in cash and warrants in amount $680 at a price of $13.30. d. Warrants to purchase Preferred shares: In March 2008, in connection with a March 2008 Founders and Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the “A warrants”), with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and (3) the sale of substantially all of the Company’s assets or substantially all of the shares to another party. In connection with the first financing round that occurred in 2016, the Company granted to certain investors warrants to purchase up to 2,775,398 D-2 Preferred shares (“D-2 warrants”) at a price per share of $9.23. The survival of D-2 warrants is limited to a period ending upon the earlier of: (i) the lapse of 5 years from closing; or (ii) a deemed liquidation event. The D-2 warrants will be exercised automatically if they are still outstanding on the final day of the warrant period as defined in the warrants grant letter, and if the fair market value of a warrant share is more than the exercise price for such share. All outstanding A warrants and D-2 warrants are classified as a long-term liability and are re-measured at each reporting date, as the underlying shares may be redeemed upon an event which is not solely in the control of the Company. On June 28, 2019, in connection with 2019 PPM, the Company included the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the “E-1 warrants”) at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years from closing. As of December 31, 2020, 200,596 E-1 warrants, 648,519 D-2 warrants and 17,925 Warrants are outstanding and may be converted into Ordinary shares. e. Deemed dividend: As part of Series E-1 Convertible Preferred shares price protection conversion rights upon the completion of an initial public offering, the Company issued 158,967 Series E-1 Convertible Preferred shares and recorded a beneficial feature of $2,114 which was accounted for as a deemed dividend and was recorded as mezzanine equity.

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
SHAREHOLDERS’ EQUITY (DEFICIT)	NOTE 10:- SHAREHOLDERS’ EQUITY (DEFICIT) a. General: On June 21, 2020, the Company’s Board of Directors resolved to consolidate the Company’s share capital by applying an additional reverse share split and cancelling the shares’ par value (See Note 1d). Following the reverse share split and the cancellation of the par value, all Ordinary shares, Convertible Preferred shares, options, convertible loans, warrants, exercise prices and per share data have been adjusted retroactively for all periods presented in these consolidated financial statements. b. Ordinary share capital is composed as follows: December 31, 2020 December 31, 2019 Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Ordinary shares with no par value 47,800,000 18,494,739 22,466,000 562,748 c. Ordinary shares rights: The Ordinary shares confer upon their holders the right to participate in the general meetings of the Company, to vote at such meetings (each share represents one vote), and to participate in any distribution of dividends or any other distribution of the Company’s property, including the distribution of surplus assets upon liquidation. d. Share option plans: The Company has authorized through its 2012 Share Option Plan, the grant of options to officers, directors, advisors, management and other key employees of up to 3,672,094 Ordinary shares. The options granted generally have a three-year vesting period and expire ten years after the date of grant. Options granted under the Company’s option plan that are cancelled or forfeited before expiration become available for future grant. As of December 31, 2020, 1,019,457 of the Company’s options were available for future grants. A summary of the status of options to employees under the Company’s option plan as of December 31, 2020 and 2019 and changes during the relevant period ended on that date is presented below: Year ended December 31, 2020 Number of options Weighted average exercise price Aggregate intrinsic value Weighted Outstanding at beginning of year 1,217,985 $ 4.62 $ 3,411 5.04 Granted 1,064,959 7.08 Exercised (395 ) 6.80 1 Forfeited and cancelled (89,157 ) 5.99 Outstanding at end of year 2,193,392 $ 5.72 $ 9,263 6.58 Exercisable options 1,306,421 $ 4.78 $ 6,686 4.63 Vested and expected to vest 2,193,392 $ 5.72 $ 9,263 6.58 Year ended December 31, 2019 Number of options Weighted average exercise price Aggregate intrinsic value Weighted Outstanding at beginning of year 1,234,955 $ 4.59 $ 4,608 5.96 Granted 82,216 8.04 Exercised (1,523 ) 4.54 4 Forfeited and cancelled (97,663 ) 6.50 Outstanding at end of year 1,217,985 $ 4.62 $ 3,411 5.04 Exercisable options 1,108,207 $ 4.29 $ 3,406 4.66 Vested and expected to vest 1,217,985 $ 4.62 $ 3,406 5.04 The Black-Scholes assumptions used to value the employee options at the grant dates are as follows: The fair value for options granted to employees during 2020 is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected volatility of 74.35%-84.77%, risk free interest rates of 0.23%-1.38%, dividend yield of 0%, and an expected term of 5-6 years. The fair value for options granted to employees during 2019 is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected volatility of 69.8%-76.14%, risk free interest rates of 2.26%-3.13%, dividend yield of 0%, and an expected term of 6-7 years. The fair value for options granted to employees during 2018 is estimated at the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions: expected volatility of 91.44%-96.87%, risk free interest rates of 3.43%-3.90%, dividend yield of 0%, and an expected term of 6-7 years. These assumptions and estimates were determined as follows: o Fair Value of Ordinary Shares- Prior to the IPO, the fair value was determined by the Company’s board of directors, with input from management and valuation reports prepared by third-party valuation specialists. After the IPO, the fair value of each Ordinary share was based on the closing price of the Company’s publicly traded Ordinary shares as reported on the date of the grant. o Risk-Free Interest Rate- The risk-free rate for the expected term of the options is based on the Black-Scholes option pricing model on the yields of U.S. Treasury securities with maturities appropriate for the expected term of employee share option awards. o Expected Term- The expected term represents the period that options are expected to be outstanding. For option grants that are considered to be “plain vanilla,” the Company determines the expected term using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. o Expected Volatility- As the Company has a short trading history for its Ordinary shares, the expected volatility is derived from the average historical share volatilities of several unrelated public companies within the Company’s industry that the Company considers to be comparable to its own business over a period equivalent to the option’s expected term. o Expected Dividend Yield- The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. As a result, an expected dividend yield of zero percent was used. The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the three years ended December 31, 2020, 2019 and 2018, was comprised as follows: Year ended December 31, 2020 2019 2018 Research and development 1,806 180 239 Marketing and business development 140 90 17 General and administrative 2,631 706 739 Total share-based compensation expense 4,577 976 995 As of December 31, 2020, there were unrecognized compensation costs of $10,071, which are expected to be recognized over a weighted average period of approximately 2.7 years. The options outstanding as of December 31, 2020 are comprised, as follows: Exercise Options as of December 31, 2020 Weighted average exercise price ($) Weighted average remaining contractual term Options exercisable as of December 31, 2020 Weighted average exercise price ($) Weighted average remaining contractual term Years Years *)0.22 249,561 *)0.22 2.21 249,561 *)0.22 2.21 1.75 107,904 1.75 2.21 107,904 1.75 2.21 3.59 83,503 3.59 2.33 83,503 3.59 2.33 5.07 260,296 5.07 3.36 260,296 5.07 3.36 9.23 200,229 9.23 4.88 200,229 9.23 4.88 3.10 29,947 3.10 5.42 29,947 3.10 5.42 3.93 51,385 3.93 5.98 51,385 3.93 5.98 4.10 20,914 4.10 6.19 20,914 4.10 6.19 4.18 1,195 4.18 6.40 1,195 4.18 6.40 7.70 66,326 7.70 6.84 66,326 7.70 6.84 8.42 7,589 8.42 7.78 5,461 8.42 7.77 8.65 15,035 8.65 7.62 10,940 8.65 7.53 8.02 46,069 8.02 8.30 35,004 8.02 8.32 6.80 58,731 6.80 9.11 14,858 6.80 9.11 6.62 904,608 6.62 9.45 168,898 6.62 9.44 11.04 90,100 11.04 9.86 - 11.04 - 2,193,392 5.72 6.58 1,306,421 4.78 4.63 *) The exercise price of the options is denominated in NIS and was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options. e. Options issued to non-employees: Outstanding options granted to consultants as of December 31, 2020 were as follows: Grant date Options as of December 31, 2020 Average price per share Options exercisable as of December 31, 2020 Exercisable March 2013 22,258 $ 1.76 22,258 March 2023 October 2013 5,719 5.06 5,719 October 2023 June 2014 5,617 5.06 5,617 June 2024 September 2014 5,719 5.06 5,719 September 2024 April 2016 5,975 3.10 5,975 April 2026 December 2016 7,170 3.93 7,170 March 2023 June 2017 197,722 4.10 136,594 June 2027 August 2017 5,617 9.29 5,617 August 2027 November 2017 17,925 7.70 17,925 March 2027 August 2019 71,700 8.18 64,195 August 2029 June 2020 88,430 6.62 - June 2030 433,852 276,789

Financial Expenses, Net

Financial Expenses, Net	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
FINANCIAL EXPENSES, NET	NOTE 11:- FINANCIAL EXPENSES, NET Year ended December 31, 2020 2019 2018 Financial expenses:  Revaluation of warrants $ 11,373 $ - $ - Foreign currency transaction loss, net - - 276 Others 17 15 42 Total financial expenses, net 11,390 15 318 Financial income: Interest from deposits (474 ) (60 ) (126 ) Revaluation of warrants - (11,365 ) (24,473 ) Foreign currency transaction gains, net (243 ) (245 ) - Other (76 ) - - Total financial income: (793 ) (11,670 ) (25,599 ) Financial expense (income), net $ 10,597 $ (11,655 ) $ (24,281 )

Basic and Diluted Net Loss (Pro

Basic and Diluted Net Loss (Profit) Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE	NOTE 12:- BASIC AND DILUTED NET LOSS (PROFIT) PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per Ordinary share: Year ended December 31, Basic net loss (profit) per share 2020 2019 2018 Numerator: Allocation of net loss (profit) $ 36,869 $ 6,905 $ (5,917 ) Preferred share preference 3,933 6,422 4,439 Net income allocated to preferred shareholders - - 1,389 Deemed dividend 2,114 - - Allocation of net loss (profit) attributable to Ordinary shareholders $ 42,916 $ 13,327 $ (89 ) Denominator: Weighted average Ordinary shares outstanding 9,582,405 562,451 561,113 Basic net loss (profit) per share $ 4.48 $ 23.69 $ (0.16 ) Diluted net loss (profit) per share: Numerator: Allocation of net loss (profit) attributable for basic computation $ 42,916 $ 13,327 $ (89 ) Revaluation of warrants to convertible preferred shares - - 616 Allocation of net loss attributable to Ordinary shareholders $ 42,916 $ 13,327 $ 527 Denominator: Number of shares used in basic calculation 9,582,405 562,451 561,113 Weighted average effect of dilutive securities Warrants to convertible preferred shares - - 52,245 Number of shares used in diluted calculation 9,582,405 562,451 613,358 Diluted net loss (profit) per share $ 4.48 $ 23.69 $ 0.86

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 13:- RELATED PARTIES Through February 2016, several management members also provided services to the Company as service providers. As of December 31, 2020 and 2019, the Company has recorded a provision for severance pay liability for such service providers in the amounts of $193 and $251, respectively. These amounts are included in “Other Liabilities”. In July 2019, the Company entered into a master service agreement with a third-party provider (the “provider”) to conduct a portion of a phase 3 clinical trial in eastern Europe for a total cost of $6,288. One of the Company’s directors serves as a director and shareholder in the provider. During the year ended December 31, 2020, the Company recognized $717 as expense as part of the research and development expenses.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14:- SUBSEQUENT EVENTS The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to identify matters that require additional disclosure. For its annual consolidated financial statements as of December 31, 2020 and for the year then ended, the Company evaluated subsequent events through March 5, 2021, the date that the consolidated financial statements were issued. During January to March 2021, 580,028 warrants to purchase Ordinary shares were exercised on a cashless basis into 115,982 Ordinary shares, out of which 419,068 warrants were exercised by related parties. In addition, during February 2021 68,491 warrants to purchase Ordinary shares were exercised into 68,491 Ordinary shares for a total consideration of $633.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of estimates	a. Use of estimates: The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates estimates, including those related to fair values of convertible preferred shares warrants, fair values of share-based awards, and contingent liabilities. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Consolidated financial statements in U.S. dollars	b. Consolidated financial statements in U.S. dollars: The accompanying consolidated financial statements have been prepared in U.S. dollars. A substantial portion of the Company’s expenses are incurred in New Israeli Shekels (“NIS”). However, the Company finances its operations mainly in U.S. dollars, a substantial portion of its expenses are incurred in U.S. dollars and potential revenues from its primary markets are anticipated to be generated in U.S. dollars. As such, the Company’s management believes that the U.S. dollar is the currency of the primary economic environment in which the Company operates. Thus, the functional and reporting currency of the Company is the U.S. dollar. Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts maintained in currencies other than the dollar are re-measured into dollars in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters”. All transaction gains and losses of the re-measurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.
Principles of consolidation	c. Principles of consolidation: The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany balances have been eliminated upon consolidation.
Reclassifications	d. Reclassifications: Certain prior years amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported consolidated net loss.
Cash equivalents	e. Cash equivalents: Cash equivalents are short-term, highly liquid investments that are readily convertible into cash with an original maturity of three months or less, at the date acquired.
Restricted cash	f. Restricted cash: Restricted cash is primarily invested in certificates of deposit and is used as security for the Company’s lease commitments and hedging activities. The following table provides a reconciliation of the cash and cash equivalents balances reported on the balance sheets and the cash, cash equivalents and restricted cash balances reported in the statements of cash flows: December 31, 2020 2019 Cash and cash equivalents, as reported on the balance sheets $ 4,319 $ 3,924 Restricted cash, as reported on the balance sheets 390 375 Restricted cash in other long-term assets, as reported on the balance sheets 199 199 Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows $ 4,908 $ 4,498
Short-term deposits	g. Short-term deposits: A Short-term bank deposit is a deposit with a maturity of more than three months but less than one year. Deposits in U.S. dollars bear interest at rates ranging from 0.4%-1.21%, per annum, as of December 31, 2020. Short-term deposits are presented at cost, which approximates market value due to their short maturities.
Long-term deposits	h. Long-term deposits: A Long-term bank deposit is a deposit with a maturity of more than one year. Deposits in U.S. dollars bear interest at rates ranging from 1.1%-1.25%, per annum, as of December 31, 2020. Long-term deposits are presented at cost.
Property and equipment, net	i. Property and equipment, net: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: % Computers, software and laboratory equipment 15 - 33 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life Down payments for property and equipment are recorded at cost and included in other long-term assets in the accompanying consolidated balance sheet. Once the corresponding property and equipment item has been received, it will be reclassified to property and equipment and depreciated.
Impairment of long-lived assets	j. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. As of December 31, 2020, no impairment losses have been identified.
Research and development expenses	k. Research and development expenses: Research and development expenses consist of personnel costs (including salaries, benefits and share-based compensation), materials, consulting fees and payments to subcontractors, chemical, manufacturing and control activities, costs associated with obtaining regulatory approvals, executing pre-clinical and clinical studies and maintenance and prosecution of the Company’s intellectual property rights. In addition, research and development expenses include overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development expenses as expenses when incurred.
Basic and diluted net loss (profit) per share	l. Basic and diluted net loss (profit) per share: The Company computes net loss (profit) per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company considered its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis, on an as-converted basis. These participating securities did not contractually require the holders of such shares to participate in the Company’s losses. As such, during the periods when the Company is in a net loss position, the net loss attributable to ordinary shareholders was not allocated to the convertible preferred shares under the two-class method as these securities did not have a contractual obligation to share in the Company’s losses. The Company’s basic net loss (profit) per share is calculated by dividing net loss (profit) attributable to ordinary shareholders by the weighted-average number of shares of Ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss (profit) per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the if-converted method based on the nature of such securities. Diluted net loss (profit) per share is the same as basic net loss (profit) per share in periods when the effects of potentially dilutive shares of Ordinary shares are anti-dilutive.
Accounting for share-based payments	m. Accounting for share-based payments: Share-based compensation expense related to share-based awards is recognized based on the fair value of the awards granted and recognized as an expense on a straight-line basis over the requisite service period for share options. The fair value of each option award is estimated on the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the input of highly subjective assumptions, including the fair value of the underlying ordinary shares, the expected term of the award, the expected volatility of the price of the Company’s Ordinary shares, risk-free interest rates, and the expected dividend yield of Ordinary shares. The assumptions used to determine the fair value of the share awards represent management’s best estimates. These estimates involve inherent uncertainties and the application of management’s judgment. Forfeitures are accounted for as they occur instead of estimating the number of awards expected to be forfeited.
Grants and participations	n. Grants and participations: Royalty-bearing grants from the Israeli Innovation Authority (“IIA”) (previously known as Office of the Chief Scientist) of the Ministry of Economy and Industry in Israel for funding of approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Non-royalty-bearing grants from the IIA MAGNET program and from European Commission’s Seventh Framework Programme for Research (FP7) for funding approved research and development projects are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred, and are presented as a deduction from research and development expenses. Since the payment of royalties is not probable when the grants are received, the Company does not record a liability for amounts received from IIA until the related revenues are recognized. In the event of failure of a project that was partly financed by IIA, the Company will not be obligated to pay any royalties or repay the amounts received. The Company recognizes participations in research and development, as a reduction from research and development expenses. The excess of the recognized amount received over the amount of research and development expenses incurred during the period is recognized as other income within operating income.
Convertible preferred shares and convertible preferred shares warrant liability	o. Convertible preferred shares and convertible preferred shares warrant liability: The terms of the convertible preferred A, A-1, B, B-1, C-1, C-2, D-1, D-3, E and E-1 shares allowed the holders to redeem shares, under certain circumstances, outside of the Company’s control. Therefore, these shares were classified as mezzanine equity on the balance sheet and not included as a component of shareholders’ deficit before the IPO. The carrying value of the convertible preferred shares is equal to cost. The Company has not adjusted the carrying value to redemption value since it is not probable that the convertible preferred shares will be redeemed. Warrants to purchase the Company’s convertible preferred shares were classified as a liability on the balance sheet, and measured at fair value, as the underlying shares are contingently redeemable (upon a deemed liquidation event) and, therefore, may obligate the Company to transfer assets at some point in the future. The warrants were subject to re-measurement to fair value at each balance sheet date and any change in fair value was recognized as a component of financial expenses, net, in the statements of operation.
Fair value of financial instruments	p. Fair value of financial instruments: The Company applies ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: ● Level 1- Observable inputs that reflect quoted prices (unadjusted) in active markets for identical assets and liabilities. ● Level 2 - Include other inputs that are directly or indirectly observable in the marketplace. ● Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value . The financial instruments carried at fair value on the Company’s consolidated balance sheets as of December 31, 2019 are warrants to convertible preferred shares classified as a liability that were reclassified to equity following the IPO. See Note 7. The following methods and assumptions were used by the Company in estimating their fair value disclosures for financial instruments: The carrying amounts of cash and cash equivalents, restricted cash, short-term deposits, long-term deposits, prepaid expenses, other receivables, trade payables, other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments.
Income taxes	q. Income taxes: The Company accounts for income taxes in accordance with ASC 740, “Income Taxes” (“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance to reduce deferred tax assets to their estimated realizable value, if needed. ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2020 and 2019, no liability for unrecognized tax benefits was recorded as a result of ASC 740. The Company’s policy is to accrue interest and penalties related to unrecognized tax benefits in its taxes on income.
Concentration of credit risks	r. Concentration of credit risks: Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel. Such investments in Israel may be in excess of insured limits and are not insured. in other jurisdictions. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk. The Company utilizes forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions.
Severance pay	s. Severance pay: All the Company’s employees who are Israeli citizens have subscribed to Section 14 of Israel’s Severance Pay Law, 5723-1963 (“Section 14”). Pursuant to Section 14, employees covered by this section are entitled to monthly deposits at a rate of 8.33% of their monthly salary, made on their behalf by the Company. Payments in accordance with Section 14 release the Company from any future severance liabilities in respect of those employees. Neither severance pay liability nor severance pay fund under Section 14 for such employees is recorded on the Company’s consolidated balance sheets. Severance pay expense for the years ended December 31, 2020 and 2019 amounted to $394 and $346, respectively.
Derivative financial instruments	t. Derivative financial instruments: The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and hedging”, as amended and related interpretations (“ASC 815”). ASC 815 requires the Company to recognize all derivatives on the balance sheet at fair value. If a derivative meets the definition of a hedge and is so designated, depending on the nature of the hedge, changes in the fair value of the derivative will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings (for fair value hedge transactions) or recognized in other comprehensive income (loss) until the hedged item is recognized in earnings (for cash flow hedge transactions). The ineffective portion of a derivative’s change in fair value is recognized in earnings. If a derivative does not meet the definition of a hedge, the changes in the fair value are included in earnings. Cash flows related to such hedges are classified as operating activities. The Company enters into option contracts in order to limit the exposure to exchange rate fluctuation associated with expenses mainly incurred in NIS. Since the derivative instruments that the Company holds do not meet the definition of hedging instruments under ASC 815, any gain or loss derived from such instruments is recognized immediately as “financial income, net”. The Company measured the fair value of the contracts in accordance with ASC 820. Foreign currency derivative contracts are classified within Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. As of December 31, 2020 and 2019, the fair value of the options contracts was $62 and $8, respectively. Profits for the year ended December 31, 2020 amounted to $81 and losses for the years ended December 31, 2019 and 2018 amounted to $10 and $0, respectively.
Contingent liabilities	u. Contingent liabilities The Company accounts for its contingent liabilities in accordance with ASC 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. The Company is occasionally a party to routine claims or litigation incidental to its business. The Company does not believe that it is a party to any pending legal proceeding that is likely to have a material adverse effect on its business, financial condition or results of operations. The Company recorded an accrual in the consolidated statement of operations, which it deems appropriate.
Recently adopted Accounting Pronouncements	v. Recently adopted Accounting Pronouncements As an “emerging growth company”, the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflect this election . In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting,” which simplifies the accounting for share-based payments granted to nonemployees for goods and services and aligns most of the guidance on such payments to the nonemployees with the requirements for share-based payments granted to employees. The Company adopted the guidance as of January 1, 2020. The adoption of the standard didn’t have a material impact on the Company’s consolidated statements of operations.
Recently Issued Accounting Pronouncements	w. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, “Leases,” which would require lessees to recognize assets and liabilities on the balance sheet for most leases, whether operating or financing, while continuing to recognize the expenses on their income statements in a manner similar to current practice. Under the new guidance, the Company would also be required to provide enhanced disclosures. The guidance states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in fiscal years beginning January 1, 2023. The Company is in the initial stage of its assessment of the new standard and is currently evaluating the timing of adoption, the quantitative impact of adoption, and the related disclosure requirements. The Company anticipates the adoption of this standard will result in an increase in its noncurrent assets, and current and noncurrent liabilities recorded on the consolidated balance sheets. The Company is currently evaluating the effect that ASU 2016-02 will have on its consolidated financial statements. In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, which simplifies the designation and measurement requirements of hedge accounting in certain situations and allows companies to better align their hedge accounting with their risk management activities. The guidance also eases certain hedge effectiveness assessment requirements, expands the eligibility of hedging strategies that may qualify for hedge accounting and modifies certain presentation and disclosure requirements. The guidance will be effective beginning January 1, 2021, and interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-12 to have a material impact on its Consolidated Statements of Operations or Cash Flows. In August 2018, the FASB issued ASU No. 2018-15, “Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The new standard requires capitalized costs to be amortized on a straight-line basis generally over the term of the arrangement, and the financial statement presentation for these capitalized costs would be the same as that of the fees related to the hosting arrangements. The guidance will be effective for the Company beginning January 1, 2021, and interim periods in fiscal years beginning January 1, 2022. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2018-15 will have on its consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes by removing a variety of exceptions within the framework of ASC 740. These exceptions include the exception to the incremental approach for intraperiod tax allocation in the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The guidance will be effective for the Company beginning January 1, 2022, and interim periods in fiscal years beginning January 1, 2023. Early adoption is permitted. The Company is currently evaluating the effect that ASU 2019-12 will have on its consolidated financial statements and related disclosures.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Restrictions on Cash and Cash Equivalents	December 31, 2020 2019 Cash and cash equivalents, as reported on the balance sheets $ 4,319 $ 3,924 Restricted cash, as reported on the balance sheets 390 375 Restricted cash in other long-term assets, as reported on the balance sheets 199 199 Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows $ 4,908 $ 4,498
Schedule of Property and equipment useful life	% Computers, software and laboratory equipment 15 - 33 Furniture and office equipment 15 Leasehold improvements Over the shorter of the term of the lease or its useful life

Prepaid Expenses and Other Re_2

Prepaid Expenses and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2020
Prepaid Expenses And Other Receivables [Abstract]
Schedule of prepaid expenses and other receivables	December 31, 2020 2019 Government authorities $ 283 $ 177 Prepaid expenses 1,888 180 Lease deposits 24 18 Others 139 42 $ 2,334 $ 417

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, 2020 2019 Cost: Computers and software $ 449 $ 389 Laboratory equipment 3,947 3,356 Furniture and office equipment 152 147 Leasehold improvements 4,478 4,353 9,026 8,245 Accumulated depreciation (3,136 ) (2,124 ) Depreciated cost $ 5,890 $ 6,121

Other Payables and Accrued Ex_2

Other Payables and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of other payables and accrued expenses	December 31, 2020 2019 Employees and payroll accruals $ 971 $ 673 Accrued expenses 681 319 IIA deferred grant 241 - Other expenses 10 6 $ 1,903 $ 998

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments under operating leases	As of December 31, 2020 2021 1,236 2022 1,181 2023 995 2024 283 2025 283 Thereafter 425 $ 4,403

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of change in the fair value of the preferred share warrants liability	December 31, 2020 2019 Beginning of year $ 12,241 $ 22,926 Issuance of warrants - 680 Change in fair value 11,373 (11,365 ) Reclassification of Warrants into equity (23,614 ) - End of period $ - $ 12,241

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	December 31, 2020 2019 Reserves and allowances $ 190 $ 173 Temporary differences 3,644 2,204 Issuance costs 957 - Loss carryforward 22,168 15,406 Deferred tax assets before valuation allowance 26,959 17,783 Less - valuation allowance (26,959 ) (17,783 ) Net deferred tax assets $ - $ -

Convertible Preferred Shares _2

Convertible Preferred Shares and Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Convertible Preferred Shares And Warrants [Abstract]
Schedule of convertible preferred shares	December 31, 2020 December 31, 2019 Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Series A Convertible Preferred shares with no par value - - 537,750 483,975 Series A-1 Convertible Preferred shares with no par value - - 896,250 798,950 Series B Convertible Preferred shares with no par value - - 597,500 566,386 Series B-1 Convertible Preferred shares with no par value - - 1,867,562 1,751,309 Series C-1 Convertible Preferred shares with no par value - - 717,000 645,923 Series C-2 Convertible Preferred shares with no par value - - 454,100 410,197 Series D-1 Convertible Preferred shares of NIS 0 par value - - 2,509,500 2,376,512 Series D-2 Convertible Preferred shares with no par value - - 2,868,000 - Series D-3 Convertible Preferred shares with no par value - - 597,500 576,944 Series E Convertible Preferred shares with no par value - - 1,135,250 851,795 Series E-1 Convertible Preferred shares with no par value - - 5,736,000 4,058,986 Total - - 17,916,412 12,520,977

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of ordinary share capital	December 31, 2020 December 31, 2019 Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Ordinary shares with no par value 47,800,000 18,494,739 22,466,000 562,748
Schedule of status of options to employees	Year ended December 31, 2020 Number of options Weighted average exercise price Aggregate intrinsic value Weighted Outstanding at beginning of year 1,217,985 $ 4.62 $ 3,411 5.04 Granted 1,064,959 7.08 Exercised (395 ) 6.80 1 Forfeited and cancelled (89,157 ) 5.99 Outstanding at end of year 2,193,392 $ 5.72 $ 9,263 6.58 Exercisable options 1,306,421 $ 4.78 $ 6,686 4.63 Vested and expected to vest 2,193,392 $ 5.72 $ 9,263 6.58 Year ended December 31, 2019 Number of options Weighted average exercise price Aggregate intrinsic value Weighted Outstanding at beginning of year 1,234,955 $ 4.59 $ 4,608 5.96 Granted 82,216 8.04 Exercised (1,523 ) 4.54 4 Forfeited and cancelled (97,663 ) 6.50 Outstanding at end of year 1,217,985 $ 4.62 $ 3,411 5.04 Exercisable options 1,108,207 $ 4.29 $ 3,406 4.66 Vested and expected to vest 1,217,985 $ 4.62 $ 3,406 5.04
Schedule of equity-based awards recognized	Year ended December 31, 2020 2019 2018 Research and development 1,806 180 239 Marketing and business development 140 90 17 General and administrative 2,631 706 739 Total share-based compensation expense 4,577 976 995
Schedule of options outstanding	Exercise Options as of December 31, 2020 Weighted average exercise price ($) Weighted average remaining contractual term Options exercisable as of December 31, 2020 Weighted average exercise price ($) Weighted average remaining contractual term Years Years *)0.22 249,561 *)0.22 2.21 249,561 *)0.22 2.21 1.75 107,904 1.75 2.21 107,904 1.75 2.21 3.59 83,503 3.59 2.33 83,503 3.59 2.33 5.07 260,296 5.07 3.36 260,296 5.07 3.36 9.23 200,229 9.23 4.88 200,229 9.23 4.88 3.10 29,947 3.10 5.42 29,947 3.10 5.42 3.93 51,385 3.93 5.98 51,385 3.93 5.98 4.10 20,914 4.10 6.19 20,914 4.10 6.19 4.18 1,195 4.18 6.40 1,195 4.18 6.40 7.70 66,326 7.70 6.84 66,326 7.70 6.84 8.42 7,589 8.42 7.78 5,461 8.42 7.77 8.65 15,035 8.65 7.62 10,940 8.65 7.53 8.02 46,069 8.02 8.30 35,004 8.02 8.32 6.80 58,731 6.80 9.11 14,858 6.80 9.11 6.62 904,608 6.62 9.45 168,898 6.62 9.44 11.04 90,100 11.04 9.86 - 11.04 - 2,193,392 5.72 6.58 1,306,421 4.78 4.63
Schedule of outstanding options granted	Grant date Options as of December 31, 2020 Average price per share Options exercisable as of December 31, 2020 Exercisable March 2013 22,258 $ 1.76 22,258 March 2023 October 2013 5,719 5.06 5,719 October 2023 June 2014 5,617 5.06 5,617 June 2024 September 2014 5,719 5.06 5,719 September 2024 April 2016 5,975 3.10 5,975 April 2026 December 2016 7,170 3.93 7,170 March 2023 June 2017 197,722 4.10 136,594 June 2027 August 2017 5,617 9.29 5,617 August 2027 November 2017 17,925 7.70 17,925 March 2027 August 2019 71,700 8.18 64,195 August 2029 June 2020 88,430 6.62 - June 2030 433,852 276,789

Financial Expenses, Net (Tables

Financial Expenses, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of financial expenses net	Year ended December 31, 2020 2019 2018 Financial expenses:  Revaluation of warrants $ 11,373 $ - $ - Foreign currency transaction loss, net - - 276 Others 17 15 42 Total financial expenses, net 11,390 15 318 Financial income: Interest from deposits (474 ) (60 ) (126 ) Revaluation of warrants - (11,365 ) (24,473 ) Foreign currency transaction gains, net (243 ) (245 ) - Other (76 ) - - Total financial income: (793 ) (11,670 ) (25,599 ) Financial expense (income), net $ 10,597 $ (11,655 ) $ (24,281 )

Basic and Diluted Net Loss (P_2

Basic and Diluted Net Loss (Profit) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per ordinary share	Year ended December 31, Basic net loss (profit) per share 2020 2019 2018 Numerator: Allocation of net loss (profit) $ 36,869 $ 6,905 $ (5,917 ) Preferred share preference 3,933 6,422 4,439 Net income allocated to preferred shareholders - - 1,389 Deemed dividend 2,114 - - Allocation of net loss (profit) attributable to Ordinary shareholders $ 42,916 $ 13,327 $ (89 ) Denominator: Weighted average Ordinary shares outstanding 9,582,405 562,451 561,113 Basic net loss (profit) per share $ 4.48 $ 23.69 $ (0.16 ) Diluted net loss (profit) per share: Numerator: Allocation of net loss (profit) attributable for basic computation $ 42,916 $ 13,327 $ (89 ) Revaluation of warrants to convertible preferred shares - - 616 Allocation of net loss attributable to Ordinary shareholders $ 42,916 $ 13,327 $ 527 Denominator: Number of shares used in basic calculation 9,582,405 562,451 561,113 Weighted average effect of dilutive securities Warrants to convertible preferred shares - - 52,245 Number of shares used in diluted calculation 9,582,405 562,451 613,358 Diluted net loss (profit) per share $ 4.48 $ 23.69 $ 0.86

General (Details)

General (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 21, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
General (Details) [Line Items]
Cash equivalents, short-term deposits and long-term deposits			$ 66,596
Net loss			(36,869)	$ (6,905)	$ 5,917
Cash flows from operating activities			(21,596)	(17,358)	$ (16,678)
Accumulated deficit			$ (132,286)	$ (93,303)
Description of reverse share split		the Company’s Board of Directors resolved to consolidate the Company’s share capital by applying a reverse share split at a ratio of 1.046:1 (the “Reverse Split Ratio”) and to cancel the shares’ par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the “Split”). The Split was applied in the same proportion and manner to all of the Company’s authorized, issued and outstanding securities, including preferred shares, options and warrants.
Aggregate net proceeds	$ 62,757
Initial Public Offering [Member]
General (Details) [Line Items]
Sale of ordinary shares (in Shares)	4,312,500
Over-Allotment Option [Member]
General (Details) [Line Items]
Sale of ordinary shares (in Shares)	562,500

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Significant Accounting Policies (Details) [Line Items]
Monthly deposits percentage rate	8.33%
Severance pay expense	$ 394	$ 346
Fair value of the options contracts	62	8
Profits (losses)	$ 81	$ 10	$ 0
Minimum [Member] | Short-Term Deposits [Member]
Significant Accounting Policies (Details) [Line Items]
Short-term deposit bearing interest percentage rate	0.40%
Minimum [Member] | Long-Term Deposits [Member]
Significant Accounting Policies (Details) [Line Items]
Long-term deposit bearing interest percentage rate	1.10%
Maximum [Member] | Short-Term Deposits [Member]
Significant Accounting Policies (Details) [Line Items]
Short-term deposit bearing interest percentage rate	1.21%
Maximum [Member] | Long-Term Deposits [Member]
Significant Accounting Policies (Details) [Line Items]
Long-term deposit bearing interest percentage rate	1.25%

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Restrictions on Cash and Cash Equivalents - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of Restrictions on Cash and Cash Equivalents [Abstract]
Cash and cash equivalents, as reported on the balance sheets	$ 4,319	$ 3,924
Restricted cash, as reported on the balance sheets	390	375
Restricted cash in other long-term assets, as reported on the balance sheets	199	199
Cash, cash equivalents, and restricted cash, as reported in the statements of cash flows	$ 4,908	$ 4,498

Significant Accounting Polici_5

Significant Accounting Policies (Details) - Schedule of Property and equipment useful life	12 Months Ended
	Dec. 31, 2020
Computers, software and laboratory equipment [Member] | Minimum [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Property, plant and equipment	15.00%
Computers, software and laboratory equipment [Member] | Maximum [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Property, plant and equipment	33.00%
Furniture and office equipment [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Property, plant and equipment	15.00%
Leasehold improvements [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Property, plant and equipment,description	Over the shorter of the term of the lease or its useful life

Prepaid Expenses and Other Re_3

Prepaid Expenses and Other Receivables (Details) - Schedule of prepaid expenses and other receivables - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of prepaid expenses and other receivables [Abstract]
Government authorities	$ 283	$ 177
Prepaid expenses	1,888	180
Lease deposits	24	18
Others	139	42
Total	$ 2,334	$ 417

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 1,012	$ 947	$ 411

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 9,026	$ 8,245
Accumulated depreciation	(3,136)	(2,124)
Depreciated cost	5,890	6,121
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	449	389
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,947	3,356
Furniture and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	152	147
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,478	$ 4,353

Other Payables and Accrued Ex_3

Other Payables and Accrued Expenses (Details) - Schedule of other payables and accrued expenses - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other payables and accrued expenses [Abstract]
Employees and payroll accruals	$ 971	$ 673
Accrued expenses	681	319
IIA deferred grant	241
Other expenses	10	6
Total	$ 1,903	$ 998

Commitments and Contingent Li_3

Commitments and Contingent Liabilities (Details) € in Thousands, $ in Thousands	Jan. 09, 2020EUR (€)	Sep. 30, 2017	Dec. 22, 2016USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
Advance payments				$ 75
Rental and lease expenses				1,035	$ 1,027	$ 1,073
Participation payments				$ 5,139
Commitments and Contingent liabilities, description		In September 2017, a suit was filed against the Company in the Tel-Aviv Magistrates Court in an amount of $250.		the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2020, no royalties have been paid or accrued.
Finder's fee			$ 250
Automatic filing machine (in Euro) | €	€ 250
Pre-payment for automatic filing machine (in Euro) | €	€ 372

Commitments and Contingent Li_4

Commitments and Contingent Liabilities (Details) - Schedule of future minimum lease payments under operating leases $ in Thousands	Dec. 31, 2020USD ($)
Schedule of future minimum lease payments under operating leases [Abstract]
2020	$ 1,236
2021	1,181
2022	995
2023	283
2024	283
Thereafter	425
Total	$ 4,403

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)$ / shares	Jun. 30, 2020₪ / shares
Fair Value Measurements (Details) [Line Items]
Weighted average fair value of the warrants, percentage		50.00%
Dividend yield		0.00%
Fair value (in Dollars) | $		$ 9,263	$ 3,406
Fair value of series A Preferred share warrants (in Dollars) | $	$ 816
IPO [Member]
Fair Value Measurements (Details) [Line Items]
Ordinary shares (in Shares) | shares	53,775
Convertible Preferred Stock [Member]
Fair Value Measurements (Details) [Line Items]
Exercise price			$ 15.95
Convertible Preferred Stock [Member] | Minimum [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			13.25
Convertible Preferred Stock [Member] | Maximum [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			$ 13.40
series E-1 Preferred share warrants [Member]
Fair Value Measurements (Details) [Line Items]
Expected volatility			69.11%
Risk free interest rates			1.82%
Dividend yield			0.00%
Expected term			2 years 3 months
Fair value (in Dollars) | $	$ 1,868		$ 563
series E-1 Preferred share warrants [Member] | IPO [Member]
Fair Value Measurements (Details) [Line Items]
Expected volatility			64.03%
Risk free interest rates			1.87%
Dividend yield			0.00%
Expected term			153 days
Convertible Preferred E-1 Shares [Member] | IPO [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			$ 12.18
Exercise price per share (in Dollars per share)			15.95
Convertible Preferred D-2 Shares [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)	$ 16		10.29
Exercise price	$ 15.95		$ 9.24
Expected volatility	78.07%		69.11%
Risk free interest rates	0.76%		1.82%
Dividend yield	0.00%		0.00%
Expected term	4 years 62 days		2 years 3 months
Fair value (in Dollars) | $	$ 20,930		$ 11,275
Cashless ordinary shares (in Shares) | shares	475,049
Convertible Preferred D-2 Shares [Member] | IPO [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)	$ 16		$ 12.18
Exercise price	$ 9.24		$ 9.24
Expected volatility	82.48%		64.03%
Risk free interest rates	0.46%		1.87%
Dividend yield	0.00%		0.00%
Expected term	219 days		153 days
Convertible Preferred A shares [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			$ 4.35
Convertible Preferred A shares [Member] | IPO [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)	$ 16
Series A Preferred Share Warrants [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			$ 0.24
Expected volatility			69.11%
Risk free interest rates			1.82%
Dividend yield			0.00%
Expected term			2 years 3 months
Fair value (in Dollars) | $			$ 403
Warrants exercised shares (in Shares) | shares	53,775
Series A Preferred Share Warrants [Member] | IPO [Member]
Fair Value Measurements (Details) [Line Items]
Share price (in Dollars per share)			$ 0.24
Exercise price | (per share)	$ 0.23			₪ 0.84
Expected volatility			64.03%
Risk free interest rates			1.87%
Dividend yield	0.00%		0.00%
Expected term			153 days
Exercise price per share (in Dollars per share)			$ 12.18

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of change in the fair value of the preferred share warrants liability - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of change in the fair value of the preferred share warrants liability [Abstract]
Beginning of year	$ 12,241	$ 22,926
Issuance of warrants		680
Change in fair value	11,373	(11,365)
Reclassification of Warrants into equity	(23,614)
End of period		$ 12,241

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Corporate tax rates	23.00%	23.00%
Amount of approximately (in Dollars)			$ 96,385,000
Statutory tax rate	23.00%	23.00%
Effective tax rate	0.00%	0.00%
Tax Cuts and Jobs Act, Change in Tax Rate, Deferred Tax Liability, Income Tax Benefit (in Dollars)		$ 0.23

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Income Taxes (Details) - Schedule of deferred tax assets [Line Items]
Deferred tax assets before valuation allowance	$ 26,959	$ 17,783
Less-valuation allowance	(26,959)	(17,783)
Net deferred tax assets
Reserves and allowances [Member]
Income Taxes (Details) - Schedule of deferred tax assets [Line Items]
Deferred tax assets before valuation allowance	190	173
Temporary differences [Member]
Income Taxes (Details) - Schedule of deferred tax assets [Line Items]
Deferred tax assets before valuation allowance	3,644	2,204
Issuance costs [Member]
Income Taxes (Details) - Schedule of deferred tax assets [Line Items]
Deferred tax assets before valuation allowance	957
Loss carryforward [Member]
Income Taxes (Details) - Schedule of deferred tax assets [Line Items]
Deferred tax assets before valuation allowance	$ 22,168	$ 15,406

Convertible Preferred Shares _3

Convertible Preferred Shares and Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	7 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 28, 2019	Mar. 31, 2008	Aug. 31, 2019	Feb. 28, 2019	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2016
Convertible Preferred Shares and Warrants (Details) [Line Items]
Convertible preferred shares (in Shares)						12,520,977
Carrying value (in Dollars)						$ 106,300
Annual interest percentage						6.00%
Issuance of warrants cost (in Dollars)						$ 1
Preferred shares (in Shares)						0		12,520,977
Dividend rights, description						the holders of Series A, A-1, B, B-1, C-1, C-2 , D-1, D-3, E and E-1 convertible preferred shares were entitled to receive on a pari passu basis, prior and in preference to the declaration or payment of any dividend or distribution to the holders of any other class of shares on an as-converted basis if any dividend or distribution was declared by the Company’s board of directors, an amount equal to 6% per annum of the applicable original issue price for such preferred shares (the “Preference Dividend”).
Liquudation rights, description						Holders of Series E-1, E preferred shares and D preferred shares were entitled to receive an amount equal to the original issuance price thereof, times 1.3, plus 6% annual interest, on the original issue price, compounded annually from the date of issuance and up to the date of liquidation for each of their shares plus an amount equal to the declared but unpaid dividends, less the any dividend preference amount previously declared and actually paid.
Securities Purchase Agreement [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Aggregate amount (in Dollars)					$ 35,000
Proceeds from debt issued (in Dollars)					$ 15,577
Converted shares (in Shares)							274,434
Private Placement Memorandum [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price	$ 13.30
Proceeds from debt issued (in Dollars)	$ 50,000			$ 30,717
Issuance costs in cash (in Dollars)	3,142
Issuance of warrants cost (in Dollars)	$ 680
Warrant [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Warrants to purchase, description			in connection with a March 2008 Founders and Share Purchase Agreement, the Company granted to an investor warrants to purchase Preferred A shares (the “A warrants”), with an exercise price of NIS 0.84 ($0.23). The A warrants may be converted at any time until the earlier of (1) consummation of an initial public offering on certain stock exchanges as set forth in the warrant terms, with net proceeds to the Company of at least $15,000 (and pre-money valuation of at least $75,000), (2) merger or consolidation of the Company with another company, and (3) the sale of substantially all of the Company’s assets or substantially all of the shares to another party.
Series A Convertible Preferred [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 1.51
Series A Convertible Preferred [Member] | Warrant [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Warrants issued (in Shares)						17,925
Series A-1 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 1.76
Preferred shares (in Shares)								798,950
Series B Convertible Preferred [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 3.60
Series B-1 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 5.06
Preferred shares (in Shares)								1,751,309
Series C-1 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 6.95
Preferred shares (in Shares)								645,923
Series C-2 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 9.23
Preferred shares (in Shares)								410,197
Series E Convertible Preferred [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price						$ 13.30
Series E-1 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price					$ 13.30
Proceeds from debt issued (in Dollars)					$ 187
Shares issued (in Shares)					1,187,887
Preferred shares (in Shares)						158,967		4,058,986
Beneficial feature value (in Dollars)						$ 2,114
Series E-1 Convertible Preferred Shares [Member] | Private Placement Memorandum [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Shares issued (in Shares)				2,596,665
Series E-1 Convertible Preferred Shares [Member] | Warrant [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Warrants issued (in Shares)						200,596
Series D-2 Convertible Preferred Shares [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Preferred shares (in Shares)
Series D-2 Convertible Preferred Shares [Member] | Warrant [Member]
Convertible Preferred Shares and Warrants (Details) [Line Items]
Share price									$ 9.23
Shares issued (in Shares)									2,775,398
Warrants to purchase, description		in connection with 2019 PPM, the Company included the following as part of its issuance costs: (i) warrants to purchase up to 200,596 E-1 Preferred shares (the “E-1 warrants”) at a price per share of $15.95 against payment of a total exercise amount of up to $3,200 and (ii) a cash fee of 10% of any new investment that were introduced by National Securities. The survival of E-1 warrants is limited to a period ending upon 4 years from closing.
Warrants issued (in Shares)						648,519

Convertible Preferred Shares _4

Convertible Preferred Shares and Warrants (Details) - Schedule of convertible preferred shares - shares	Dec. 31, 2020	Dec. 31, 2019
Number of shares
Convertible preferred shares, Authorized	0	17,916,412
Convertible Preferred shares, Issued and outstanding	0	12,520,977
Series A Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		537,750
Convertible Preferred shares, Issued and outstanding		483,975
Series A-1 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		896,250
Convertible Preferred shares, Issued and outstanding		798,950
Series B Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		597,500
Convertible Preferred shares, Issued and outstanding		566,386
Series B-1 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		1,867,562
Convertible Preferred shares, Issued and outstanding		1,751,309
Series C-1 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		717,000
Convertible Preferred shares, Issued and outstanding		645,923
Series C-2 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		454,100
Convertible Preferred shares, Issued and outstanding		410,197
Series D-1 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		2,509,500
Convertible Preferred shares, Issued and outstanding		2,376,512
Series D-2 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		2,868,000
Convertible Preferred shares, Issued and outstanding
Series D-3 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		597,500
Convertible Preferred shares, Issued and outstanding		576,944
Series E Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		1,135,250
Convertible Preferred shares, Issued and outstanding		851,795
Series E-1 Convertible Preferred Shares [Member]
Number of shares
Convertible preferred shares, Authorized		5,736,000
Convertible Preferred shares, Issued and outstanding	158,967	4,058,986

Shareholders' Equity (Deficit_2

Shareholders' Equity (Deficit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	1,064,959	82,216
Granted stock option expire period	10 years
Expected dividend yield	0.00%
Unrecognized compensation costs (in Dollars)	$ 10,071
Recognized over weighted average period	2 years 255 days
Employee Stock Options [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Expected volatility, minimum	74.35%	69.80%	91.44%
Expected volatility, maximum	84.77%	76.14%	96.87%
Risk free interest rates, minimum	0.23%	2.26%	3.43%
Risk free interest rates, maximum	1.38%	3.13%	3.90%
Expected dividend yield	0.00%	0.00%	0.00%
Employee Stock Options [Member] | Minimum [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Expected term	5 years	6 years	6 years
Employee Stock Options [Member] | Maximum [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Expected term	6 years	7 years	7 years
2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Stock option vesting period	3 years
Stock options available for future grants (in Shares)	1,019,457
Officers [Member] | 2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	3,672,094
Directors [Member] | 2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	3,672,094
Advisors [Member] | 2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	3,672,094
Management [Member] | 2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	3,672,094
Other Key Employees [Member] | 2012 Share Option Plan [Member]
Shareholders' Equity (Deficit) (Details) [Line Items]
Options granted (in Shares)	3,672,094

Shareholders' Equity (Deficit_3

Shareholders' Equity (Deficit) (Details) - Schedule of ordinary share capital - shares	Dec. 31, 2020	Dec. 31, 2019
Number of shares
Ordinary shares Authorized	47,800,000	22,520,977
Ordinary shares Issued	18,494,739	562,748
Ordinary shares outstanding	18,494,739	562,748

Shareholders' Equity (Deficit_4

Shareholders' Equity (Deficit) (Details) - Schedule of status of options to employees - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of status of options to employees [Abstract]
Number of Options, Outstanding, Beginning balance (in Shares)	1,217,985	1,234,955
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 4.62	$ 4.59
Aggregate intrinsic value, Beginning balance (in Dollars)	$ 3,411	$ 4,608
Weighted Average Remaining Contractual life (years), Beginning Outstanding	5 years 14 days	5 years 350 days
Number of Options, Granted (in Shares)	1,064,959	82,216
Weighted Average Exercise Price, Granted	$ 7.08	$ 8.04
Number of Options, Exercised (in Shares)	(395)	(1,523)
Weighted Average Exercise Price, Exercised	$ 6.80	$ 4.54
Aggregate intrinsic value, Exercised	$ 5.72	$ 4
Number of Options, Forfeited and cancelled (in Shares)	(89,157)	(97,663)
Weighted Average Exercise Price, Forfeited and cancelled	$ 5.99	$ 6.50
Number of Options, Outstanding, Ending balance (in Shares)	2,193,392	1,217,985
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	$ 5.72	$ 4.62
Aggregate intrinsic value, Ending balance (in Dollars)	$ 9,263	$ 3,411
Weighted Average Remaining Contractual life (years), Ending Outstanding	6 years 211 days	5 years 14 days
Number of Options, Exercisable options (in Shares)	1,306,421	1,108,207
Weighted Average Exercise Price, Exercisable options	$ 4.78	$ 4.29
Aggregate intrinsic value, Exercisable options (in Dollars)	$ 6,686	$ 3,406
Weighted Average Remaining Contractual life (years), Exercisable options	4 years 229 days	4 years 240 days
Number of Options, Vested and expected to vest (in Shares)	2,193,392	1,217,985
Weighted Average Exercise Price, Vested and expected to vest	$ 5.72	$ 4.62
Aggregate intrinsic value, Vested and expected to vest (in Dollars)	$ 9,263	$ 3,406
Weighted Average Remaining Contractual life (years), Vested and expected to vest	6 years 211 days	5 years 14 days

Shareholders' Equity (Deficit_5

Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]
Total share-based compensation expense	$ 4,577	$ 976	$ 995
Research and development expense [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]
Total share-based compensation expense	1,806	180	239
Marketing and business development [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]
Total share-based compensation expense	140	90	17
General and administrative expense [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of equity-based awards recognized [Line Items]
Total share-based compensation expense	$ 2,631	$ 706	$ 739

Shareholders' Equity (Deficit_6

Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding - $ / shares		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		2,193,392
Weighted average exercise price (in Dollars per share)		$ 5.72	$ 4
Weighted average remaining contractual term (year)		6 years 211 days
Number options exercisable		1,306,421
Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 4.78
Weighted average remaining contractual term (year)		4 years 229 days
Exercise Price 0.22 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average remaining contractual term (year)		2 years 76 days
Number options exercisable	[1]
Exercise Price 0.22 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average remaining contractual term (year)		2 years 76 days
Exercise Price 1.75 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		107,904
Weighted average exercise price (in Dollars per share)		$ 1.75
Weighted average remaining contractual term (year)		2 years 76 days
Number options exercisable		107,904
Exercise Price 1.75 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 1.75
Weighted average remaining contractual term (year)		2 years 76 days
Exercise Price 3.59 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		83,503
Weighted average exercise price (in Dollars per share)		$ 3.59
Weighted average remaining contractual term (year)		2 years 120 days
Number options exercisable		83,503
Exercise Price 3.59 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 3.59
Weighted average remaining contractual term (year)		2 years 120 days
Exercise Price 5.07 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		260,296
Weighted average exercise price (in Dollars per share)		$ 5.07
Weighted average remaining contractual term (year)		3 years 131 days
Number options exercisable		260,296
Exercise Price 5.07 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 5.07
Weighted average remaining contractual term (year)		3 years 131 days
Exercise Price 9.23 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		200,229
Weighted average exercise price (in Dollars per share)		$ 9.23
Weighted average remaining contractual term (year)		4 years 321 days
Number options exercisable		200,229
Exercise Price 9.23 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 9.23
Weighted average remaining contractual term (year)		4 years 321 days
Exercise Price 3.10 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		29,947
Weighted average exercise price (in Dollars per share)		$ 3.10
Weighted average remaining contractual term (year)		5 years 153 days
Number options exercisable		29,947
Exercise Price 3.10 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 3.10
Weighted average remaining contractual term (year)		5 years 153 days
Exercise Price 3.93 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		51,385
Weighted average exercise price (in Dollars per share)		$ 3.93
Weighted average remaining contractual term (year)		5 years 357 days
Number options exercisable		51,385
Exercise Price 3.93 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 3.93
Weighted average remaining contractual term (year)		5 years 357 days
Exercise Price 4.10 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		20,914
Weighted average exercise price (in Dollars per share)		$ 4.10
Weighted average remaining contractual term (year)		6 years 69 days
Number options exercisable		20,914
Exercise Price 4.10 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 4.10
Weighted average remaining contractual term (year)		6 years 69 days
Exercise Price 4.18 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		1,195
Weighted average exercise price (in Dollars per share)		$ 4.18
Weighted average remaining contractual term (year)		6 years 146 days
Number options exercisable		1,195
Exercise Price 4.18 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 4.18
Weighted average remaining contractual term (year)		6 years 146 days
Exercise Price 7.70 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		66,326
Weighted average exercise price (in Dollars per share)		$ 7.70
Weighted average remaining contractual term (year)		6 years 306 days
Number options exercisable		66,326
Exercise Price 7.70 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 7.70
Weighted average remaining contractual term (year)		6 years 306 days
Exercise Price 8.42 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		7,589
Weighted average exercise price (in Dollars per share)		$ 8.42
Weighted average remaining contractual term (year)		7 years 284 days
Number options exercisable		5,461
Exercise Price 8.42 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 8.42
Weighted average remaining contractual term (year)		7 years 281 days
Exercise Price 8.65 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		15,035
Weighted average exercise price (in Dollars per share)		$ 8.65
Weighted average remaining contractual term (year)		7 years 226 days
Number options exercisable		10,940
Exercise Price 8.65 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 8.65
Weighted average remaining contractual term (year)		7 years 193 days
Exercise Price 8.02 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		46,069
Weighted average exercise price (in Dollars per share)		$ 8.02
Weighted average remaining contractual term (year)		8 years 109 days
Number options exercisable		35,004
Exercise Price 8.02 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 8.02
Weighted average remaining contractual term (year)		8 years 116 days
Exercise Price 6.80 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		58,731
Weighted average exercise price (in Dollars per share)		$ 6.80
Weighted average remaining contractual term (year)		9 years 40 days
Number options exercisable		14,858
Exercise Price 6.80 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 6.80
Weighted average remaining contractual term (year)		9 years 40 days
Exercise Price 6.62 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		904,608
Weighted average exercise price (in Dollars per share)		$ 6.62
Weighted average remaining contractual term (year)		9 years 164 days
Number options exercisable		168,898
Exercise Price 6.62 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 6.62
Weighted average remaining contractual term (year)		9 years 160 days
Exercise Price 11.04 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Number of options outstanding		90,100
Weighted average exercise price (in Dollars per share)		$ 11.04
Weighted average remaining contractual term (year)		9 years 313 days
Number options exercisable
Exercise Price 11.04 [Member] | Option [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of options outstanding [Line Items]
Weighted average exercise price (in Dollars per share)		$ 11.04
Weighted average remaining contractual term (year)
[1]	The exercise price of the options is denominated in NIS and was translated to U.S. dollars in the table above using the exchange rate as of the issuance date of the options.

Shareholders' Equity (Deficit_7

Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	433,852
Options exercisable	276,789
March 2013 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	22,258
Average Exercise price per share (in Dollars per share) | $ / shares	$ 1.76
Options exercisable	22,258
Exercisable	March 2023
October 2013 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	5,719
Average Exercise price per share (in Dollars per share) | $ / shares	$ 5.06
Options exercisable	5,719
Exercisable	October 2023
June 2014 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	5,617
Average Exercise price per share (in Dollars per share) | $ / shares	$ 5.06
Options exercisable	5,617
Exercisable	June 2024
September 2014 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	5,719
Average Exercise price per share (in Dollars per share) | $ / shares	$ 5.06
Options exercisable	5,719
Exercisable	September 2024
April 2016 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	5,975
Average Exercise price per share (in Dollars per share) | $ / shares	$ 3.10
Options exercisable	5,975
Exercisable	April 2026
December 2016 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	7,170
Average Exercise price per share (in Dollars per share) | $ / shares	$ 3.93
Options exercisable	7,170
Exercisable	March 2023
June 2017 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	197,722
Average Exercise price per share (in Dollars per share) | $ / shares	$ 4.10
Options exercisable	136,594
Exercisable	June 2027
August 2017 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	5,617
Average Exercise price per share (in Dollars per share) | $ / shares	$ 9.29
Options exercisable	5,617
Exercisable	August 2027
November 2017 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	17,925
Average Exercise price per share (in Dollars per share) | $ / shares	$ 7.70
Options exercisable	17,925
Exercisable	March 2027
August 2019 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	71,700
Average Exercise price per share (in Dollars per share) | $ / shares	$ 8.18
Options exercisable	64,195
Exercisable	August 2029
June 2020 [Member]
Shareholders' Equity (Deficit) (Details) - Schedule of outstanding options granted [Line Items]
Options outstanding	88,430
Average Exercise price per share (in Dollars per share) | $ / shares	$ 6.62
Exercisable	June 2030

Financial Expenses, Net (Detail

Financial Expenses, Net (Details) - Schedule of financial expenses net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of financial expenses net [Abstract]
Revaluation of warrants	$ 11,373
Foreign currency transaction loss, net			276
Others	17	15	42
Total financial expenses, net	11,390	15	318
Interest from deposits	(474)	(60)	(126)
Revaluation of warrants		(11,365)	(24,473)
Foreign currency transaction gains, net	(243)	(245)
Other	(76)
Total financial income:	(793)	(11,670)	(25,599)
Financial expense (income), net	$ 10,597	$ (11,655)	$ (24,281)

Basic and Diluted Net Loss (P_3

Basic and Diluted Net Loss (Profit) Per Share (Details) - Schedule of basic and diluted net loss per ordinary share - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of basic and diluted net loss per ordinary share [Abstract]
Allocation of net loss (profit)	$ 36,869	$ 6,905	$ (5,917)
Preferred share preference	3,933	6,422	4,439
Net income allocated to preferred shareholders			1,389
Deemed dividend	2,114
Allocation of net loss (profit) attributable to Ordinary shareholders	$ 42,916	$ 13,327	$ (89)
Weighted average Ordinary shares outstanding (in Shares)	9,582,405	562,451	561,113
Basic net loss (profit) per share (in Dollars per share)	$ 4.48	$ 23.69	$ (0.16)
Allocation of net loss (profit) attributable for basic computation	$ 42,916	$ 13,327	$ (89)
Revaluation of warrants to convertible preferred shares			616
Allocation of net loss attributable to Ordinary shareholders	$ 42,916	$ 13,327	$ 527
Number of shares used in basic calculation (in Shares)	9,582,405	562,451	561,113
Weighted average effect of dilutive securities Warrants to convertible preferred shares (in Shares)			52,245
Number of shares used in diluted calculation (in Shares)	9,582,405	562,451	613,358
Diluted net loss per share (in Dollars per share)	$ 4.48	$ 23.69	$ 0.86

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Parties (Details) [Line Items]
Service providers in amount		$ 193	$ 251
Research and development expenses		16,954	$ 14,083	$ 12,550
Eastern Europe [Member]
Related Parties (Details) [Line Items]
Cost	$ 6,288
Director [Member]
Related Parties (Details) [Line Items]
Research and development expenses		$ 717

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	1 Months Ended		2 Months Ended
	Mar. 31, 2021	Feb. 28, 2021	Mar. 31, 2021
Subsequent Events (Details) [Line Items]
Warrants to purchase ordinary shares	580,028	68,491	580,028
Ordinary shares exercised	115,982	68,491
Stock Issued During Period, Value, Conversion of Units (in Dollars)		$ 633
Related Parties [Member]
Subsequent Events (Details) [Line Items]
Warrants exercised			419,068